118 related articles for article (PubMed ID: 3840612)
21. Optimal control of cyclophosphamide-induced emesis.
Stewart A
Oncology; 1996 Jun; 53 Suppl 1():32-8. PubMed ID: 8692548
[TBL] [Abstract][Full Text] [Related]
22. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
23. [Antiemetic treatments associated with antineoplastic chemotherapy].
Tres Sánchez A; Sáez Martínez MJ; Mayordomo Cámara JJ; Guillén Lloveria G; Sáenz Cusi A
An Med Interna; 1990 May; 7(5):229-32. PubMed ID: 2102716
[TBL] [Abstract][Full Text] [Related]
24. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
25. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
26. Antiemetic activity of megestrol acetate in patients receiving chemotherapy.
Zang J; Hou M; Gou HF; Qiu M; Wang J; Zhou XJ; Luo de Y; Yang Y; Jiang M; Cao D; Bi F; Xu F; Shen Y; Yi C
Support Care Cancer; 2011 May; 19(5):667-73. PubMed ID: 20419494
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
29. Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy.
Tsavaris N; Mylonakis N; Bacoyiannis C; Kosmas C; Kalergis G; Iakovidis V; Tzaninis D; Kosmidis P
Oncol Rep; 1998; 5(5):1147-55. PubMed ID: 9683826
[TBL] [Abstract][Full Text] [Related]
30. Methylprednisolone for the control of CMF-induced emesis.
Chiara S; Campora E; Lionetto R; Bruzzi P; Rosso R
Am J Clin Oncol; 1987 Jun; 10(3):264-7. PubMed ID: 3296735
[TBL] [Abstract][Full Text] [Related]
31. An analysis of the antiemetic protection of metoclopramide plus dexamethasone in Chinese patients receiving moderately high emetogenic chemotherapy.
Molassiotis A; Mok TS; Yam BM; Yung H
Eur J Cancer Care (Engl); 2002 Jun; 11(2):108-13. PubMed ID: 12099946
[TBL] [Abstract][Full Text] [Related]
32. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
33. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
34. Acute and anticipatory emesis in breast cancer patients.
Fernández-Marcos A; Martín M; Sanchez JJ; Rodriguez-Lescure A; Casado A; López Martin JA; Diaz-Rubio E
Support Care Cancer; 1996 Sep; 4(5):370-7. PubMed ID: 8883231
[TBL] [Abstract][Full Text] [Related]
35. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
36. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Marschner NW; Adler M; Nagel GA; Christmann D; Fenzl E; Upadhyaya B
Eur J Cancer; 1991; 27(9):1137-40. PubMed ID: 1835624
[TBL] [Abstract][Full Text] [Related]
37. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy.
Sigsgaard T; Herrstedt J; Christensen P; Andersen O; Dombernowsky P
Support Care Cancer; 2000 May; 8(3):233-7. PubMed ID: 10789966
[TBL] [Abstract][Full Text] [Related]
38. The antiemetic efficacy of thiethylperazine and methylprednisolone versus thiethylperazine and placebo in breast cancer patients treated with adjuvant chemotherapy (fluorouracil, doxorubicin and cyclophosphamide). A randomized, double-blind, cross-over trial.
Diaz-Rubio E; Martin M; Rosell R; Valerdi JJ; Gonzalez-Larriba JL; Barriga JJ
Acta Oncol; 1991; 30(3):339-42. PubMed ID: 2036244
[TBL] [Abstract][Full Text] [Related]
39. Is an antiemetic prophylactic treatment needed for patients submitted to consecutive days of 5-fluorouracil? An observational study.
Tumori; 2001; 87(6):379-82. PubMed ID: 11989589
[TBL] [Abstract][Full Text] [Related]
40. Influence of bromopride in the prophylaxis of nausea associated with fluorescein angiography.
Lira RP; Moraes LF; Oliveira Júnior Md; Melo AL; Vasconcelos MS
Arq Bras Oftalmol; 2007; 70(1):105-8. PubMed ID: 17505728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
